Results 241 to 250 of about 94,624 (285)
Some of the next articles are maybe not open access.
Cancer, 1994
Prostate specific antigen (PSA) is the most accurate serum marker for prostate cancer. However, sensitivity and specificity are suboptimal, especially at the intermediate levels between 4.1 and 10.0 ng/ml (monoclonal). For intermediate PSA levels, PSA density (PSAD) provides unique information regarding the need for biopsy and the likelihood of ...
Mitchell C Benson, Carl A Olsson
exaly +3 more sources
Prostate specific antigen (PSA) is the most accurate serum marker for prostate cancer. However, sensitivity and specificity are suboptimal, especially at the intermediate levels between 4.1 and 10.0 ng/ml (monoclonal). For intermediate PSA levels, PSA density (PSAD) provides unique information regarding the need for biopsy and the likelihood of ...
Mitchell C Benson, Carl A Olsson
exaly +3 more sources
Journal of Urology, 2008
Prostate specific antigen, prostate specific antigen density and transition zone density have been previously identified as prostate cancer detection tools. Recent studies suggest that prostate specific antigen may be increasingly accurate for detecting clinically significant high grade prostate cancer (Gleason grade 7 or greater).
Christopher S Elliott, Rajesh Shinghal
exaly +3 more sources
Prostate specific antigen, prostate specific antigen density and transition zone density have been previously identified as prostate cancer detection tools. Recent studies suggest that prostate specific antigen may be increasingly accurate for detecting clinically significant high grade prostate cancer (Gleason grade 7 or greater).
Christopher S Elliott, Rajesh Shinghal
exaly +3 more sources
Cancer, 1994
Prostate specific antigen (PSA) is useful as a tumor marker for monitoring patients with prostate cancer after definitive therapy. Limitations have been noted when PSA was used for the early detection of prostate cancer. The use of prostate specific antigen density [PSAD = PSA (ng/ml)/prostate volume (cc)] has been suggested to differentiate benign ...
W P Evans
exaly +3 more sources
Prostate specific antigen (PSA) is useful as a tumor marker for monitoring patients with prostate cancer after definitive therapy. Limitations have been noted when PSA was used for the early detection of prostate cancer. The use of prostate specific antigen density [PSAD = PSA (ng/ml)/prostate volume (cc)] has been suggested to differentiate benign ...
W P Evans
exaly +3 more sources
PROSTATE-SPECIFIC ANTIGEN DENSITY
Urologic Clinics of North America, 1997Nearly 20 years have passed since PSA was definitively identified. Throughout this period, its clinical application as a tumor marker has expanded significantly. Today, besides monitoring prostate cancer therapy, PSA is being used extensively in mass screening programs for early detection of adenocarcinoma of the prostate and has become the most ...
M C, Beduschi, J E, Oesterling
openaire +2 more sources
Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial [PDF]
Urology, 2002 This prospective, multicenter European Prostate Cancer Detection study evaluated the value and performance of the molecular forms of prostate-specific antigen (PSA) and their derivatives in combination with prostate gland and transition zone volumes in early detection of prostate cancer in patients with PSA levels between 4 and 10 ng/mL.
Djavan, Bob +8 more
openaire +2 more sources
Journal of Urology, 1994
We compared prostate specific antigen (PSA) to PSA density for 3 clinical uses: detection of nonpalpable prostate cancer, staging of clinically localized prostate cancer and prediction of PSA detectability following radical prostatectomy. Of 153 men with normal digital rectal examinations undergoing prostate biopsy 25% had prostate cancer.
K, Shinohara +3 more
openaire +2 more sources
We compared prostate specific antigen (PSA) to PSA density for 3 clinical uses: detection of nonpalpable prostate cancer, staging of clinically localized prostate cancer and prediction of PSA detectability following radical prostatectomy. Of 153 men with normal digital rectal examinations undergoing prostate biopsy 25% had prostate cancer.
K, Shinohara +3 more
openaire +2 more sources
Urology, 1994
We attempt to correlate prebiopsy serum prostate-specific antigen (PSA) concentration and prostate-specific antigen density (PSAD) with histologic results of prostate biopsy.Sixty-two consecutive patients underwent prostate biopsy because of elevated PSA greater than 4 ng/mL and/or abnormal findings on digital rectal examination (DRE).
R, Bare, L, Hart, D L, McCullough
openaire +2 more sources
We attempt to correlate prebiopsy serum prostate-specific antigen (PSA) concentration and prostate-specific antigen density (PSAD) with histologic results of prostate biopsy.Sixty-two consecutive patients underwent prostate biopsy because of elevated PSA greater than 4 ng/mL and/or abnormal findings on digital rectal examination (DRE).
R, Bare, L, Hart, D L, McCullough
openaire +2 more sources
Effect of finasteride on prostate-specific antigen density
Urology, 1994Prostate-specific antigen density (PSAD) has been proposed as a diagnostic marker for prostate cancer. Because treatment with finasteride may affect PSAD differently in men with BPH compared with men with BPH plus prostate cancer, we evaluated the diagnostic utility of PSAD in men treated with finasteride for twelve months.Data for this analysis were ...
G J, Gormley +5 more
openaire +2 more sources
International Journal of Urology, 1996
Objective: To study the significance of prostate specific antigen (PSA) and prostate specific antigen density (PSAD) for predicting the risk of occult metastatic disease and extra‐prostatic invasion of prostate cancer in patients receiving radical prostatectomy.Patients and methods: The cases of 41 consecutive patients who underwent radical ...
M, Masai, H, Ito, T, Kotake, K, Nagao
openaire +2 more sources
Objective: To study the significance of prostate specific antigen (PSA) and prostate specific antigen density (PSAD) for predicting the risk of occult metastatic disease and extra‐prostatic invasion of prostate cancer in patients receiving radical prostatectomy.Patients and methods: The cases of 41 consecutive patients who underwent radical ...
M, Masai, H, Ito, T, Kotake, K, Nagao
openaire +2 more sources
Actas urologicas espanolas, 2003
With serum prostate specific antigen (PSA) levels of 4.1 to 10 ng/ml a significant number of patients are unnecessary subjected to biopsy. We try to determine if the calculation of prostate specific antigen density (PSAD) and prostate specific antigen density of the transition zone (PSADTZ) improve the capacity to discriminate between non-malignant ...
J M, Martínez Jabaloyas +5 more
openaire +2 more sources
With serum prostate specific antigen (PSA) levels of 4.1 to 10 ng/ml a significant number of patients are unnecessary subjected to biopsy. We try to determine if the calculation of prostate specific antigen density (PSAD) and prostate specific antigen density of the transition zone (PSADTZ) improve the capacity to discriminate between non-malignant ...
J M, Martínez Jabaloyas +5 more
openaire +2 more sources